OncLive Profiles Exelixis' Anticancer Compound Cabozantinib
Tuesday, January 24, 2012 at 9:28AM OncLive - Dec. 28, 2011
OncLive’s Ben Leach delves into the development program for biotechnology company Exelixis’ highly anticipated anticancer compound Cabozantinib. Focusing on the capacity of the drug to treat different tumor types, Leach explains its novelty and potential.
“The investigational compound Cabozantinib (formerly known as XL184) has generated much excitement in recent years for its ability to target multiple pathways involved in the development of cancer, thus allowing it to be used against more than 1 tumor type.
‘Our goal is to bring active compounds to patients who have unmet medical need,’ said Gisela M. Schwab, MD, Exelixis’ executive vice president and chief medical officer. ‘We set out to really create a compound that was broadly effective.’
Cabozantinib is such a compound.”
Read the full story here.